IL128645A0 - Method of treating post menopausal diseases including osteoporosis - Google Patents

Method of treating post menopausal diseases including osteoporosis

Info

Publication number
IL128645A0
IL128645A0 IL12864597A IL12864597A IL128645A0 IL 128645 A0 IL128645 A0 IL 128645A0 IL 12864597 A IL12864597 A IL 12864597A IL 12864597 A IL12864597 A IL 12864597A IL 128645 A0 IL128645 A0 IL 128645A0
Authority
IL
Israel
Prior art keywords
diseases including
including osteoporosis
treating post
post menopausal
menopausal diseases
Prior art date
Application number
IL12864597A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL128645A0 publication Critical patent/IL128645A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
IL12864597A 1996-09-06 1997-09-03 Method of treating post menopausal diseases including osteoporosis IL128645A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24
PCT/US1997/015474 WO1998009519A1 (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases, including osteoporosis

Publications (1)

Publication Number Publication Date
IL128645A0 true IL128645A0 (en) 2000-01-31

Family

ID=26699738

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12864597A IL128645A0 (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases including osteoporosis

Country Status (16)

Country Link
EP (2) EP0927029A4 (zh)
JP (2) JP2002515046A (zh)
KR (2) KR20000068473A (zh)
CN (2) CN1236313A (zh)
AR (1) AR008155A1 (zh)
AU (2) AU4409797A (zh)
BR (2) BR9711676A (zh)
CA (2) CA2264943A1 (zh)
CO (2) CO5070658A1 (zh)
CZ (1) CZ76699A3 (zh)
IL (1) IL128645A0 (zh)
NO (2) NO991097D0 (zh)
PL (2) PL332278A1 (zh)
TR (2) TR199900506T2 (zh)
TW (1) TW411273B (zh)
WO (2) WO1998009619A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5749998A (en) * 1997-02-11 1998-08-26 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2196003A (en) * 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
ES2112994T3 (es) * 1992-09-15 1998-04-16 Merrell Pharma Inc Analogos de clomifeno no metabolizables utilizados en el tratamiento de tumores resistentes al tamoxifeno.
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
TW411273B (en) 2000-11-11
WO1998009619A1 (en) 1998-03-12
AR008155A1 (es) 1999-12-09
PL332278A1 (en) 1999-08-30
JP2002515047A (ja) 2002-05-21
TR199900504T2 (xx) 1999-06-21
WO1998009519A1 (en) 1998-03-12
KR20000068473A (ko) 2000-11-25
JP2002515046A (ja) 2002-05-21
CO4920218A1 (es) 2000-05-29
CO5070658A1 (es) 2001-08-28
NO991097L (no) 1999-03-05
CN1236299A (zh) 1999-11-24
NO991097D0 (no) 1999-03-05
AU4247397A (en) 1998-03-26
NO991096D0 (no) 1999-03-05
BR9711676A (pt) 1999-08-24
EP0927029A4 (en) 2001-06-13
NO991096L (no) 1999-03-05
CA2264943A1 (en) 1998-03-12
EP0929216A4 (en) 2001-04-04
CN1236313A (zh) 1999-11-24
EP0927029A1 (en) 1999-07-07
EP0929216A1 (en) 1999-07-21
CZ76699A3 (cs) 1999-08-11
CA2264775A1 (en) 1998-03-12
PL332038A1 (en) 1999-08-16
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
KR20000068472A (ko) 2000-11-25
TR199900506T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
PL328831A1 (en) Combined treatment of osteoporosis
GB9617780D0 (en) Method of treatment
GB9620892D0 (en) Methods of treating RAF mediated diseases
EP0946180A4 (en) METHODS FOR STIMULATING BONE FORMATION
PL339910A1 (en) Method of treating alzheimer disease
GB9715295D0 (en) Novel method of treatment
HUP9902029A3 (en) Control of healing process
EP0933803A4 (en) PLASMA TREATMENT METHOD
GB9712866D0 (en) Novel method of treatment
IL128645A0 (en) Method of treating post menopausal diseases including osteoporosis
GB9715298D0 (en) Novel method of treatment
PL328925A1 (en) Method of treating bipolar disorders
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
EP1124555A4 (en) METHOD FOR TREATING NEURODEGENERATIVE DISEASES
ZA972606B (en) Method of treatment of waste water
EG21073A (en) Method of producing cement
GB9507825D0 (en) Method of treatment
IL123283A0 (en) Improved method of treating water
GB9600888D0 (en) Method of treatment
PL309903A1 (en) Method of obtaining chloroderivatives of aromatic nitroanilins
GB9602867D0 (en) Methods of treating raf mediated diseases
EG24157A (en) Novel method of treatment
EG24199A (en) Novel method of treatment
GB9822698D0 (en) Method of treating neurodegenerative diseases